Latest news with #FSH
Technical.ly
7 days ago
- Business
- Technical.ly
Pittsburgh Public Schools seeks $2M software deal with FSH Tech to rethink cafeteria logistics
A Philly-based startup is reaching across the state with a proposed $2 million software deal to modernize operations at Pittsburgh Public Schools. The potential 10-year contract with Pittsburgh Public Schools (PPS) food services would provide custom-built software for the department, helping it bring five million meals to students annually. FSH Technologies would turn the complex, paperwork-based process of food distribution into a more modern endeavor, putting all the logistics onto one platform. 'The public sector has long been underserved, especially in technology,' Lilly Chen, founder and CEO of FSH Technologies, told 'They deserve access to modern technology with modern [user experience] and [user interface] that actually work for their process, because every single town, city, school district has their own unique way of operating.' PPS food services' current system involves using multiple software programs and manual methods like Excel spreadsheets and PDFs for various tasks, according to the director of the department, Malik Hamilton. With about 22,000 meals to serve daily, along with after-school snacks, school dinners and catering contracts with local private schools or daycares, the food services department needed a system that could integrate all its needs, Hamilton said, including regulatory compliance, production records, menu planning and forecasting. 'We have a lot of paperwork, a lot of things that we have to keep track of,' Hamilton said. 'We were looking for [a software program] that is more robust than what we're currently using and that could help us grow into some of the things that we want to do moving forward.' The new platform that FSH Tech is building has a unified database, so the department can share data about menus, ingredients, vendors and more, Chen said. When schools place food orders with the district's central kitchen, the platform allows them to select the menu item, how many need to be made, when it's being served and if the item is a main dish, side or dessert. The system automatically figures out what ingredients and how much of each are needed, placing the order with third-party vendors when the menu is made. Although the food services budget is not part of PPS's recent deficit issues — because the department funds its operations through meal sales — the cost of the platform was still a key factor in choosing FSH, Hamilton said. FSH 'did not come in as the lowest bidder,' Hamilton said. But he was optimistic the program would ultimately help the department save money because, as food costs rise, it would allow them to 'closely monitor financial decisions that are being made in each building.' The PPS board will vote on the proposed contract on May 28. Chen and Hamilton both said they are confident it would be approved. Software 'assembled to order' for public-sector needs FSH's goal was to create a system that used food efficiently and was easy to use for the district's employees because it impacts students' ability to access food, Chen said. 'There's a realness to what software does,' she said. 'It serves real people who have lives.' The wider problem of outdated workflows or software platforms that don't totally align with an organization's operations isn't unique to the Pittsburgh school district, Chen said. It's a common issue often caused by budget constraints — especially in the public sector. A former machine learning infrastructure engineer at Meta, Chen's interest in public sector technology sparked while she was volunteering for Philadelphia Mayor Cherelle Parker's Open for Business initiative. She was helping to build a tool that would be a one-stop shop for Philadelphia businesses to access resources and grant information. That experience showed her how long and inefficient the process can be for developing government technology tools. 'It kind of shocked me,' she said. 'Everyone is so well-intentioned, so motivated to help, and yet we aren't getting solutions delivered to the people that we promise that we're going to deliver them to.' Most software is 'opinionated software,' she said, meaning that it's built to work a certain way using a specific method, but every unique city and agency has its own way of doing things. Instead, FSH focuses on composable software, pieces with specific functions that can be 'assembled to order,' with a specific focus on municipalities, she said. The private sector doesn't offer enough products for the public sector, she said. It builds tools that work for them and government agencies have to try to make them work, despite having different processes and serving unique groups of people. With the PPS contract, FSH learned what the needs of the school system are, the roles that employees play and designed the platform to check those boxes. 'We always say,' Chen said, 'that we build technology for people first that works for your process.'
India Today
14-05-2025
- Health
- India Today
New saliva test aims to reduce IVF side effects and improve pregnancy rates
A simple saliva test can help improve the chances of IVF, according to a new study by Swedish findings, published in peer-reviewed Frontiers in Endocrinology, has found that a genetic test could reduce harmful side effects for women undergoing fertility by Yvonne Lundberg Giwercman from Lund University, the research highlights how personalised hormone therapy, based on a woman's genetic makeup, can lead to more successful About 15% of couples of reproductive age struggle with infertility. A growing number of people are postponing parenthood, leading to a sharp increase in assisted reproduction methods like IVF treatments come with challenges. The procedure involves hormone therapy to stimulate egg production, but nearly 75% of IVF attempts to 20% of women experience side effects, some requiring emergency care.'A major issue is that doctors currently have to guess which hormone treatment is best for each woman,' said Ida Hjelmr, the study's first author and a laboratory researcher at Lund find a solution, the team analysed the genes of 1,466 women undergoing discovered that women with a specific version of the FSH receptor gene responded better to biological hormones, while others did better with synthetic matching treatment to genetic type, success rates improved significantly.'We saw a 38% increase in births among women who received hormone therapy that matched their gene variation. That's 110 more babies for every 1,000 women treated,' said make this process faster and more accessible, the team developed a simple oral swab test that shows the ideal hormone treatment within an hour, visible as a pink or yellow test is expected to be available by early 2026, said Giwercman, who is also the CEO of the company that developed the oral swab researchers have applied for a patent and launched a company, Dx4Life AB, to bring the product to hope the test will lead to more successful IVF outcomes while reducing health risks and healthcare Watch
Yahoo
13-05-2025
- Business
- Yahoo
Granata Bio Announces Strategic Investment and Collaboration with Gedeon Richter to Expand U.S. Fertility Market Leadership
BOSTON, May 13, 2025 /PRNewswire/ -- Granata Bio ("Granata"), a U.S.-based biotechnology company focused on advancing fertility therapeutics, today announced a strategic partnership with Gedeon Richter Plc. ("Richter"), a global leader in women's health. The agreement includes Richter's acquisition of a significant equity stake in Granata and the appointment of a Richter representative to Granata's Board of Directors. Richter issued a press release today outlining the partnership and highlighting the strategic importance of the collaboration in expanding its presence in the United States and strengthening its Women's Health Care portfolio. The partnership brings together two highly complementary organizations. Granata contributes deep U.S. market expertise, including strong relationships with key opinion leaders (KOLs), clinical development and regulatory strategy, and commercial execution. Richter offers global scale, proven manufacturing capabilities, and a long-standing commercial presence in reproductive health markets worldwide. In addition to the equity investment, the companies have signed a binding term sheet for the co-development of BEMFOLA®, Richter's recombinant follicle stimulating hormone (FSH) for the U.S. market, and a royalty purchase agreement for Granata's proprietary human menopausal gonadotropin (hMG) program, aligning long-term commercial interests in the fertility space. "We're proud to partner with Gedeon Richter, an organization whose global footprint and manufacturing excellence perfectly complement Granata Bio's strengths in the U.S. market. This collaboration brings together the best of both companies: deep therapeutic expertise, operational agility, and a shared commitment to improving access to fertility care," said Evan Sussman, CEO and Co-Founder of Granata Bio. Stephen Medeiros, Chief Operating Officer of Granata Bio, added, "FSH is the most prescribed gonadotropin by volume and represents a cornerstone of ovarian stimulation treatment. The addition of BEMFOLA® to our pipeline significantly strengthens our portfolio, providing coverage across all major IVF product categories. Together, these assets position us to better support the evolving needs of patients and providers in the U.S. fertility landscape." This partnership, coupled with the recent acquisition of Oviva Therapeutics, further solidifies Granata's leadership position in the fertility sector, as it continues to build a portfolio of innovative assets designed to improve outcomes and access for individuals seeking reproductive care. About Granata Bio Granata Bio is a U.S. based biopharmaceutical company committed to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending female health span. For more information, please visit and LinkedIn. About Gedeon Richter Plc. Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at View original content to download multimedia: SOURCE Granata Bio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hans India
13-05-2025
- Health
- Hans India
A simple oral swab test before IVF likely to boost success rate
Swedish researchers have developed a simple oral swab test, which can help boost the success rate of the in vitro fertilization (IVF) procedure. IVF treatment involves stimulating the woman's ovaries to mature many eggs, which are then retrieved and fertilised with sperm in the laboratory before being returned to the uterus. There are two different types of hormone treatments to choose from for egg maturation: biological or synthetic. Besides the risk of serious side effects, the therapies sometimes require women to go into intensive care -- and many attempts at IVF fail. Selecting which therapy is best for the woman has become a major challenge. While mapping genes is costly and takes time, the new simple oral swab test within an hour shows which hormone therapy is most suitable. 'Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments, and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,' said Yvonne Lundberg Giwercman, professor at Lund University. A total of 1,466 women undergoing IVF treatment in Sweden were included in the study, and 475 were randomised to two different hormone treatments while the rest were controls. Using gene sequencing, the team mapped the action of the gene follicle-stimulating hormone (FSH), which is known to play an important role in egg maturation. The study identified that women with a particular variant of the FSH receptor (FSHR) gene that mediates the action of the hormone responded best to the biological hormone treatment, while others benefited from receiving the synthetic type of hormone. To decode the genetic profile, the team turned to the oral swab test, which proved to be significantly efficient. Within an hour, it produced results that can be seen with the naked eye as a pink or yellow colour. By knowing the woman's genetic profile in advance, we can increase the number of successful pregnancies, said Giwercman, in the study published in the journal Frontiers in Endocrinology.
Yahoo
12-05-2025
- Business
- Yahoo
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. Lead author on the poster is Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy. Presentation Details: Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA) Session: Developmental Therapeutics—Immunotherapy Session Type: Poster Session Date & Time: June 2, 2025, 1:30 PM – 4:30 PM CT Abstract ID: TPS2682 About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Sign in to access your portfolio
